Arcturus Therapeutics Holdings Inc
Research Arcturus Therapeutics Holdings Inc (ARCT) on Bullrun: market cap USD 438.85M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARCT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 438.85M
- Financial periodQ2 2026
- RevenueUSD 880.00K
- Net income-USD 23.79M
- Free cash flow-USD 19.91M
Valuation Snapshot
latest market cap is USD 438.85M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 82.03M | -USD 65.78M | -USD 74.50M | n/a | -2.4 | USD 230.91M | USD 25.00M | USD 213.99M |
| FY2024 | USD 152.31M | -USD 80.94M | -USD 60.40M | n/a | -3 | USD 237.03M | USD 28.55M | USD 240.98M |
| FY2023 | USD 166.80M | -USD 29.73M | -USD 21.00M | n/a | -1.12 | USD 292.01M | USD 30.22M | USD 278.51M |
| FY2022 | USD 206.00M | USD 9.35M | USD 24.27M | n/a | 0.35 | USD 391.88M | USD 60.66M | USD 270.31M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 438.85M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 174.18M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 458.19M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 842.59M | 8.7 | n/a | n/a |
| 2022 | 2022-12-30 | USD 450.38M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 976.03M | n/a | n/a | n/a |
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Arcturus Therapeutics Holdings Inc's market cap?
Arcturus Therapeutics Holdings Inc's market capitalization is USD 438.85M.
What does Arcturus Therapeutics Holdings Inc do?
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency.